Last reviewed · How we verify

NCT05645939: Paradox

Association of Obesity and Cardiovascular Outcomes in Hypertrophic Cardiomyopathy

Status unknown Last updated 27 July 2023
What this trial tests

trial testing Diasgnosis of hypertrophic cardiomyopathy in Obesity in 30,000 participants. Status unknown.

Timeline
1 July 2022
Primary endpoint
31 October 2024
31 December 2024

Quick facts

Lead sponsorAjou University School of Medicine
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30,000
Start date1 July 2022
Primary completion31 October 2024
Estimated completion31 December 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Ajou University School of Medicine

Who can join

20 and older, any sex, with Obesity or Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators evaluated the association between various measures of adiposity \[BMI and waist circumference (WC)\] and clinical outcomes in Asian patients with hypertrophic cardiomyopathy, using a nationwide population based cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

Other Ajou University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05645939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing